A clinical trial to determine the optimum dose of radioiodine for treating the left over Thyroid cancer cells after surgery
- Conditions
- Health Condition 1: null- Differentiated Thyroid Cancer
- Registration Number
- CTRI/2011/12/002291
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 422
Patients with disease confirmed to be limited to the thyroid bed only by clinical, radiological, per-operative, and post-surgical 131I scintigraphic examination and having no evidence of extra thyroidal or distant metastases at the time of radioiodine treatment.
Patients with tumor size (T1-3)
Patients with less than total/near total thyroidectomy.
T4 tumor size.
Aggressive histology such as tall cell and columnar cell papillary carcinoma, hurthle cell carcinoma and poorly differentiated carcinoma.
If at any time, extra thyroidal disease in the form of either nodal or distant metastases was detected before the first-dose outcome.
Pregnant and breast-feeding patients.
Patient who were otherwise fulfilling all criteria of inclusion, but did not give consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method